Retatrutide vs VIP (Vasoactive Intestinal Peptide)

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Retatrutide

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.

Full details →

VIP (Vasoactive Intestinal Peptide)

VIP is a 28-amino acid neuropeptide with wide-ranging effects throughout the body. It acts as a neurotransmitter, neuromodulator, and immune regulator with particular importance in gut and lung function.

Full details →

Side-by-Side Comparison

AspectRetatrutideVIP (Vasoactive Intestinal Peptide)
MechanismTriple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation.Binds to VPAC1 and VPAC2 receptors to modulate immune responses, regulate circadian rhythms, promote vasodilation, and support barrier function in gut and lungs. Has potent anti-inflammatory effects.
Typical DosageClinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials.Intranasal: 50-200mcg 1-3 times daily for chronic inflammatory conditions. Some protocols use subcutaneous administration. Dosing varies by condition.
AdministrationSubcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved.Intranasal is most common for inflammatory conditions. Subcutaneous injection also used. Must be stored cold and protected from light.
Side EffectsSimilar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity.May cause nasal irritation, flushing, headache, or temporary diarrhea. Generally well-tolerated at standard doses.
Best For

Key Differences

Unique to Retatrutide:

Unique to VIP (Vasoactive Intestinal Peptide):

Ready to Learn More?